NCT05208866View on ClinicalTrials.gov

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

PHASE3TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

February 10, 2022

Primary Completion Date

June 29, 2022

Study Completion Date

July 29, 2022

Conditions
Polycystic Kidney Disease, Adult
Interventions
DRUG

Lixivaptan

Oral vasopressin V2 receptor antagonist

Trial Locations (1)

18107

Northeast Clinical Research Center, LLC, Bethlehem

Sponsors
All Listed Sponsors
collaborator

Centessa Pharmaceuticals plc

INDUSTRY

lead

Palladio Biosciences

INDUSTRY

NCT05208866 - Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303 | Biotech Hunter | Biotech Hunter